ANDA 219032, held by Contract Pharmacal. Fexofenadine Hydrochloride.
As of Nov 21, 2026, ANDA 219032 (Fexofenadine Hydrochloride), held by Contract Pharmacal, was first approved by FDA on Feb 28, 2025, with 0 approved supplements and 0 published complete response letters.
Uses temporarily relieves these symptoms due to hay fever or other respiratory allergies: runny nose sneezing itchy, watery eyes itching of the nose or throat
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 28, 2025 | Original application | Approved | None posted |
| Fexofenadine Hydrochloride60MG · tablet;oral | Fexofenadine Hydrochloride | OTC |
| Fexofenadine Hydrochloride180MG · tablet;oral | Fexofenadine Hydrochloride | OTC |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters